Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody
出版年份 2021 全文链接
标题
Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody
作者
关键词
-
出版物
Nature Communications
Volume 12, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-11
DOI
10.1038/s41467-021-21239-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- K18-hACE2 mice develop respiratory disease resembling severe COVID-19
- (2021) Claude Kwe Yinda et al. PLoS Pathogens
- Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
- (2020) Yushun Wan et al. JOURNAL OF VIROLOGY
- Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
- (2020) Michael Letko et al. Nature Microbiology
- Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2
- (2020) Ren-Di Jiang et al. CELL
- A Mouse Model of SARS-CoV-2 Infection and Pathogenesis
- (2020) Shi-Hui Sun et al. Cell Host & Microbe
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
- (2020) Linlin Bao et al. NATURE
- Evaluation of K18-hACE2 Mice as a Model of SARS-CoV-2 Infection
- (2020) Gregory Brett Moreau et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment
- (2020) Jing Sun et al. CELL
- A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies
- (2020) Ahmed O. Hassan et al. CELL
- Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
- (2020) James Brett Case et al. Cell Host & Microbe
- A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
- (2020) Wafaa B. Alsoussi et al. JOURNAL OF IMMUNOLOGY
- Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
- (2020) Lihong Liu et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- A perspective on potential antibody-dependent enhancement of SARS-CoV-2
- (2020) Ann M. Arvin et al. NATURE
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Structural basis of a shared antibody response to SARS-CoV-2
- (2020) Meng Yuan et al. SCIENCE
- Animal and translational models of SARS-CoV-2 infection and COVID-19
- (2020) M. D. Johansen et al. Mucosal Immunology
- The coding capacity of SARS-CoV-2
- (2020) Yaara Finkel et al. NATURE
- A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
- (2020) Kenneth H. Dinnon et al. NATURE
- SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function
- (2020) Emma S. Winkler et al. NATURE IMMUNOLOGY
- Antibodies may curb pandemic before vaccines
- (2020) Jon Cohen SCIENCE
- Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
- (2020) M. Alejandra Tortorici et al. SCIENCE
- ACE2 mouse models: a toolbox for cardiovascular and pulmonary research
- (2020) Hongpeng Jia et al. Nature Communications
- A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
- (2020) Tal Noy-Porat et al. Nature Communications
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease
- (2020) Joseph W. Golden et al. JCI Insight
- Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
- (2020) Fatai S. Oladunni et al. Nature Communications
- A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge
- (2020) Yfat Yahalom-Ronen et al. Nature Communications
- Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
- (2018) Martin R. Gaudinski et al. PLOS MEDICINE
- Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset
- (2017) Zhe Chen et al. JOURNAL OF INFECTIOUS DISEASES
- Extended therapeutic window for post-exposure treatment of ricin intoxication conferred by the use of high-affinity antibodies
- (2017) Tal Noy-Porat et al. TOXICON
- Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
- (2016) Xiang-Qing Yu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life
- (2015) Tal Noy-Porat et al. BIOCONJUGATE CHEMISTRY
- Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
- (2015) Davide Corti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
- (2014) Vaheh Oganesyan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
- (2009) Johannes F. Scheid et al. NATURE
- Isolation and Chimerization of a Highly Neutralizing Antibody Conferring Passive Protection against Lethal Bacillus anthracis Infection
- (2009) Ronit Rosenfeld et al. PLoS One
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started